Baseline characteristics and prior treatment history
| Characteristic . | All treated (N = 85) . | Lenalidomide refractory (n = 51) . |
|---|---|---|
| Age, median (range), y | 66 (38-85) | 66 (38-85) |
| ECOG performance status | ||
| 0-1 | 78 (92) | 47 (92) |
| 2 | 7 (8) | 4 (8) |
| No. of prior lines | ||
| Median (range) | 2 (1-4) | 2 (1-4) |
| 1 | 20 (24) | 6 (12) |
| 2 | 40 (47) | 26 (51) |
| 3 | 23 (27) | 18 (35) |
| >3 | 2 (2) | 1 (2) |
| Prior ASCT | 62 (73) | 33 (65) |
| Prior bortezomib | 85 (100) | 51 (100) |
| Prior IMiD | 85 (100) | 51 (100) |
| Lenalidomide | 81 (95) | 51 (100) |
| Pomalidomide | 13 (15) | 9 (18) |
| Thalidomide | 21 (25) | 11 (22) |
| Refractory to:* | ||
| Lenalidomide | 51 (60) | 51 (100) |
| Pomalidomide | 11 (13) | 9 (18) |
| Bortezomib | 26 (31) | 21 (41) |
| PI + IMiD | 25 (29) | 22 (43) |
| Characteristic . | All treated (N = 85) . | Lenalidomide refractory (n = 51) . |
|---|---|---|
| Age, median (range), y | 66 (38-85) | 66 (38-85) |
| ECOG performance status | ||
| 0-1 | 78 (92) | 47 (92) |
| 2 | 7 (8) | 4 (8) |
| No. of prior lines | ||
| Median (range) | 2 (1-4) | 2 (1-4) |
| 1 | 20 (24) | 6 (12) |
| 2 | 40 (47) | 26 (51) |
| 3 | 23 (27) | 18 (35) |
| >3 | 2 (2) | 1 (2) |
| Prior ASCT | 62 (73) | 33 (65) |
| Prior bortezomib | 85 (100) | 51 (100) |
| Prior IMiD | 85 (100) | 51 (100) |
| Lenalidomide | 81 (95) | 51 (100) |
| Pomalidomide | 13 (15) | 9 (18) |
| Thalidomide | 21 (25) | 11 (22) |
| Refractory to:* | ||
| Lenalidomide | 51 (60) | 51 (100) |
| Pomalidomide | 11 (13) | 9 (18) |
| Bortezomib | 26 (31) | 21 (41) |
| PI + IMiD | 25 (29) | 22 (43) |
Unless otherwise noted, all data are n (%).
Refractoriness was based on most recent prior medication.